Literature DB >> 18655187

Quercetin-induced ubiquitination and down-regulation of Her-2/neu.

Jae-Hoon Jeong1, Jee Young An, Yong Tae Kwon, Lu-Yuan Li, Yong J Lee.   

Abstract

Her-2/neu (ErbB2) is a transmembrane tyrosine kinase and acts as a co-receptor for the other EGFR family members. It is well known that high expression of Her-2/neu is associated with a poor prognosis in breast cancer. Quercetin, a flavonoid present in many vegetables and fruits, has been studied extensively as a chemoprevention agent in several cancer models. In this study, we observed that quercetin decreased the level of Her-2/neu protein in time- and dose-dependent manners and also inhibited the downstream survival PI3K-Akt signaling pathway in Her-2/neu-overexpressing breast cancer SK-Br3 cells. We also observed that quercetin induced polyubiquitination of Her-2/neu. When the proteasome pathway was blocked by MG-132 during quercetin treatment, accumulation of the NP-40 insoluble form of Her-2/neu occurred. Interestingly, data from immunocomplex studies revealed that quercetin promoted interaction between Her-2/neu and Hsp90 which is a molecular chaperone involved in stabilization of Her-2/neu. In this condition, inhibition of Hsp90 activity by a specific inhibitor, geldanamycin (GA), or intracellular ATP depletion caused dissociation of Hsp90 from Her-2/neu and promoted ubiquitination and down-regulation of Her-2/neu protein. In addition, the carboxyl terminus of Hsc70-interacting protein (CHIP), a chaperone-dependent E3 ubiquitin ligase, played a crucial role in the quercetin-induced ubiquitination of Her-2/neu. Inhibition of tyrosine kinase activity of Her-2/neu by quercetin could indicate an lateration in the Her-2/neu structure which promotes CHIP recruitments and down-regulation of Her-2/neu. We believe that by using quercetin, new therapeutic strategies can be developed to treat Her-2/neu overexpressing cancers. (c) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18655187      PMCID: PMC2575035          DOI: 10.1002/jcb.21859

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  45 in total

1.  Caspase-dependent cleavage of ErbB-2 by geldanamycin and staurosporin.

Authors:  O Tikhomirov; G Carpenter
Journal:  J Biol Chem       Date:  2001-06-11       Impact factor: 5.157

2.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Authors:  D J Slamon; B Leyland-Jones; S Shak; H Fuchs; V Paton; A Bajamonde; T Fleming; W Eiermann; J Wolter; M Pegram; J Baselga; L Norton
Journal:  N Engl J Med       Date:  2001-03-15       Impact factor: 91.245

3.  Drug-induced ubiquitylation and degradation of ErbB receptor tyrosine kinases: implications for cancer therapy.

Authors:  Ami Citri; Iris Alroy; Sara Lavi; Chanan Rubin; Wanping Xu; Nicolas Grammatikakis; Cam Patterson; Len Neckers; David W Fry; Yosef Yarden
Journal:  EMBO J       Date:  2002-05-15       Impact factor: 11.598

4.  ErbB2 is essential in the prevention of dilated cardiomyopathy.

Authors:  Steven A Crone; You-Yang Zhao; Lian Fan; Yusu Gu; Susumu Minamisawa; Yang Liu; Kirk L Peterson; Ju Chen; Ronald Kahn; Gianluigi Condorelli; John Ross; Kenneth R Chien; Kuo-Fee Lee
Journal:  Nat Med       Date:  2002-05       Impact factor: 53.440

5.  Sensitivity of mature Erbb2 to geldanamycin is conferred by its kinase domain and is mediated by the chaperone protein Hsp90.

Authors:  W Xu; E Mimnaugh; M F Rosser; C Nicchitta; M Marcu; Y Yarden; L Neckers
Journal:  J Biol Chem       Date:  2000-11-08       Impact factor: 5.157

Review 6.  The therapeutic potential of flavonoids.

Authors:  H K Wang
Journal:  Expert Opin Investig Drugs       Date:  2000-09       Impact factor: 6.206

Review 7.  Geldanamycin as a potential anti-cancer agent: its molecular target and biochemical activity.

Authors:  L Neckers; T W Schulte; E Mimnaugh
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

Review 8.  Mechanism of action of trastuzumab and scientific update.

Authors:  J Baselga; J Albanell; M A Molina; J Arribas
Journal:  Semin Oncol       Date:  2001-10       Impact factor: 4.929

9.  Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy.

Authors:  Cemil Ozcelik; Bettina Erdmann; Bernhard Pilz; Nina Wettschureck; Stefan Britsch; Norbert Hübner; Kenneth R Chien; Carmen Birchmeier; Alistair N Garratt
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-18       Impact factor: 11.205

10.  Prevention of breast tumour development in vivo by downregulation of the p185neu receptor.

Authors:  M Katsumata; T Okudaira; A Samanta; D P Clark; J A Drebin; P Jolicoeur; M I Greene
Journal:  Nat Med       Date:  1995-07       Impact factor: 53.440

View more
  24 in total

1.  Ubiquitination-dependent regulation of signaling receptors in cancer.

Authors:  Wei-Chun Huangfu; Serge Y Fuchs
Journal:  Genes Cancer       Date:  2010-07

Review 2.  Influence of berry polyphenols on receptor signaling and cell-death pathways: implications for breast cancer prevention.

Authors:  Harini S Aiyer; Anni M Warri; Denzel R Woode; Leena Hilakivi-Clarke; Robert Clarke
Journal:  J Agric Food Chem       Date:  2012-02-22       Impact factor: 5.279

3.  Molecular imaging of TGFβ-induced Smad2/3 phosphorylation reveals a role for receptor tyrosine kinases in modulating TGFβ signaling.

Authors:  Shyam Nyati; Katrina Schinske; Dipankar Ray; Mukesh K Nyati; Mukesh Nyati; Brian Dale Ross; Alnawaz Rehemtulla
Journal:  Clin Cancer Res       Date:  2011-09-26       Impact factor: 12.531

4.  Fibroblast growth factor receptor 3 (FGFR3) is a strong heat shock protein 90 (Hsp90) client: implications for therapeutic manipulation.

Authors:  Melanie B Laederich; Catherine R Degnin; Gregory P Lunstrum; Paul Holden; William A Horton
Journal:  J Biol Chem       Date:  2011-04-12       Impact factor: 5.157

5.  Loss of the Nuclear Pool of Ubiquitin Ligase CHIP/STUB1 in Breast Cancer Unleashes the MZF1-Cathepsin Pro-oncogenic Program.

Authors:  Haitao Luan; Bhopal Mohapatra; Timothy A Bielecki; Insha Mushtaq; Sameer Mirza; Tameka A Jennings; Robert J Clubb; Wei An; Dena Ahmed; Rokaya El-Ansari; Matthew D Storck; Nitish K Mishra; Chittibabu Guda; Yuri M Sheinin; Jane L Meza; Srikumar Raja; Emad A Rakha; Vimla Band; Hamid Band
Journal:  Cancer Res       Date:  2018-03-06       Impact factor: 12.701

6.  Inhibition of mammary tumor growth and metastases to bone and liver by dietary grape polyphenols.

Authors:  Linette Castillo-Pichardo; Michelle M Martínez-Montemayor; Joel E Martínez; Kristin M Wall; Luis A Cubano; Suranganie Dharmawardhane
Journal:  Clin Exp Metastasis       Date:  2009-03-18       Impact factor: 5.150

7.  Grape polyphenols inhibit Akt/mammalian target of rapamycin signaling and potentiate the effects of gefitinib in breast cancer.

Authors:  Linette Castillo-Pichardo; Suranganie F Dharmawardhane
Journal:  Nutr Cancer       Date:  2012       Impact factor: 2.900

8.  Prognostic implications of carboxyl-terminus of Hsc70 interacting protein and lysyl-oxidase expression in human breast cancer.

Authors:  Neill Patani; Wen Jiang; Robert Newbold; Kefah Mokbel
Journal:  J Carcinog       Date:  2010-11-12

Review 9.  Correlation of human epidermal growth factor receptor protein expression and colorectal cancer.

Authors:  Wen-Juan Yang; Xing-Jie Shen; Xiao-Xia Ma; Zhi-Gang Tan; Yan Song; Yi-Tong Guo; Mei Yuan
Journal:  World J Gastroenterol       Date:  2015-07-28       Impact factor: 5.742

10.  Hsp70 exerts oncogenic activity in the Apc mutant Min mouse model.

Authors:  Yun Tao; Jeannette S Messer; Kathleen H Goss; John Hart; Marc Bissonnette; Eugene B Chang
Journal:  Carcinogenesis       Date:  2016-05-04       Impact factor: 4.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.